FDA approves Gilead’s Bixlenvo for adults with suppressed HIV
AI Summary- FDA approved Gilead’s Bixlenvo for adults with virologically suppressed HIV.
- Bixlenvo combines 75 mg of bictegravir with 50 mg of lenacapavir.
- ARTISTRY-1 participants had a median age of 60 and averaged 28 treatment years.